Estrogen Replacement Therapy for Breast Cancer Patients

ONCOLOGY

Volumn 11, Issue 10, 1997, Pages 1491-1497

  Colditz, Graham A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

BREAST CANCER; CANCER SURVIVAL; ESTROGEN THERAPY; HEART DISEASE; HORMONE RESPONSE; OBESITY; OSTEOPOROSIS; REVIEW; TREATMENT PLANNING;

BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; GONADAL STEROID HORMONES; HUMANS; OSTEOPOROSIS; RISK FACTORS; SURVIVORS; TAMOXIFEN;

EID: 0030730783     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Pike MC, Spicer DV, Dahmoush L, et al: Estrogens, progestogens, normal breast cell proliferation and breast cancer risk. Epidemtol Rev 15:17-35, 1993.
2. Anderson TJ, Battersby S, King RB, et al Oral contraceptive use influences resting breast proliferation Hum Pathol 20:1139-44, 1989.
3. Williams G, Anderson E, Howell A, et al: Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal breast Int J Cancer 48:206-10, 1991.
4. Clarke C, Sutherland R: Progestin regulation of cellular proliferation: update 1993, in Horwitz K (ed) Endocrine Reviews. Monograph 1. Endocrine aspects of cancer, pp 132-135. Bethesdu, Maryland, Endocrinology Society. 1993.
5. Myers J, Connor R: Cell proliferation in fibrocystic disease and postmenopausal breast ducts measured by thymidine labeling. Cancer 50:746-51, 1982.
6. Key TJ, Pike MC: The role of estrogens and progestogens in the epidemiology of and prevention ot breast cancer. Eur J Cancer Clin Oncol 24:29-43, 1988.
7. Hankmson SE, Willett WC, Manson JE, et al: Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 6:1297-1302, 1995.
8. Thomas H, Key T, Allen D, et al. Reversal of relation between body mass index and endogenous estrogen concentiations with menopausal status. J Natl Cancer Inst 89:396-397, 1997
9. Tretli S: Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570.000 women in Norway Int J Cancer 44:23-30, 1989.
10. Adami HO, Rimsten A, Stenkvist B, et al: Influence of height, weight, and obesity on risk of breast cancer in an unselected Swedish population. Br J Cancer 36:787-92, 1977
11. Hankinson SE, Manson JE, London ST, et al: Laboratory reproducibility of endogenous hormone levels in postmenopausal women. Cancer Epidemiol Biomarkers Prev 3:51-6, 1994
12. Toniolo P, Levitz M, Zelenvich-Jacquotte A, et al: A prospective study of endogenous estrogens and breast cancer in post-menopausal women. J Natl Cancer Inst 87:190-197, 1995.
13. Cauley J, Lucas F, Kuller L, et al for the Study of Osteoporotic Fractures Research Group. Is bone mineral density a biological marker of a woman's cumulative exposure to estrogen? Rochester, Minnesota. American Epidemiological Society. 1997.
14. Sowers MR, Wallace RB, Lemke JH: Correlates of mid-radius bone density among postmenopausal women: a community study. Am J Clin Nutri 41:1045-53, 1985.
15. Cauley J, Gutai J, Kuller L, et al: Black-white differences in serum sex hormones and bone mineral density. Am J Epidemiol 139:1035-1046, 1994.
16. Cauley J, Lucas F, Kuller L, et al: Bone mineral density and risk of breast cancer in older women. The Study of Osteoporotic Fractures. JAMA 276:1404-1408, 1996.
17. Zhang Y, Kiel D, Kreger B, et al: Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336:611-617. 1997.
18. Olsson H, Hagglund G: Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures. Am J Epidemiol 136:422-427, 1992.
19. Perrson I, Adami H, McLaughlin J, et al: Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden). Cancer Causes Control 5:523-528, 1994.
20. Grady D, Rubin S, Pemti D, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117:1016-1037, 1992.
21. Erlik Y, Meldrum D, Judd H: Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol 59:403-407, 1982.
22. Hagen C, Christtansen M, Tranbol I: Climacteric symptoms, fat mass, and plasma concentrations of LH, FSH, Prl. oestradiol-17-beta and androstenedione in the early post-menopausal period. Acta Endocrinol 101:87-92, 1982.
23. Mango D, Scirpa P, Battaglia F, et al: Plasma androstenedione and oestrone levels in the climacteric syndrome. Maturitas 5:245-250, 1984
24. Longcope C, Crawford S, McKinlay S: Endogenous estrogens, relationship between estrone, estradiol, non-protein bound estradiol, and hot flashes and lipids. Menopause 3:77-84, 1996.
25. Bauer D, Browner W, Cauley J: Factors associated with appendicular bone mass in older women. Ann Intern Med 118:657-665, 1993.
26. Schuurman A, van den Brandt P, Goldbohm R: Exogenous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands cohort study. Cancer Causes Control 6:416-424, 1995.
27. Colditz G, Willett W, Speizer F: Hormones and breast cancer. N Engl J Med 333:1357-1358, 1995.
28. Steinberg K, Thaker S, Smith S, et al: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265:1985-1990, 1991.
29. Sillero-Arenas M. Delgado-Rodriguez M, Rodngues-Canteras R, et al: Menopausal hormone replacement therapy and risk of breast cancer a meta-analysis. Obstet Gynecol 79:286-294, 1992.
30. Colditz G, Egan K, Stampfer M: Hormone replacement therapy and risk of breast cancer, results from epidemiologic studies. Am J Obstet Gynecol 168:1473-1480, 1993.
31. Dupont W, Page D. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151:67-72, 1991.
32. Steinberg K, Smith S, Thacker S, et al: Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis, Epidemiology 5:415-421, 1994.
33. Colditz GA, Hankinson SE, Hunter DJ, et al: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332:1589-1593, 1995.
34. Stanford JL, Weiss NS, Voigt LF, et al Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274:137-142, 1995.
35. Newcomb PA, Longnecker MP, Storer BE, et al: Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidermal 142:788-795, 1995.
36. Zhang S, Folsom AR, Sellers TA, et al: Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. Cancer 76:275-283, 1995.
37. Coates R, Clark W, Eley J, et al: Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst 82:1684-1692, 1990.
38. Early Breast Cancer Triahsts' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy Lancet 339:1-15, 1992.
39. Bergkvist L, Adami H-O, Persson I, et al: Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 130:221-228, 1989.
40. Strickland D, Gambrell R, Butzin C, et al. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obsatet Gynecol 80 400-404, 1992.
41. Willis D, Calle E, Miracle-McMahill H, et al: Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7:449-457, 1996.
42. Sturgeon S, Schairer C, Brinton L: Evidence of a healthy estrogen user survivor effect. Epidemiology 6.227-231, 1995.
43. Brinton L: Editorial. Cancer Causes Control 7:569-571, 1996.
44. Cobleigh MA, Berris RF, Bush T, et al: Estrogen replacement therapy in breast cancer survivors. A time for change. JAMA 272:540-545, 1994.
45. McNeil C: ERT for breast cancer survivors: a hot debate runs on little data. J Natl Cancer Inst 87:1047-1050, 1995.
46. Lobo RA: Hormone replacement therapy. Oestrogen replacement after treatment for breast cancer? Lancet 341:1313-1314, 1993.
47. Sands R, Boshoff C, Jones A, et al: Current opinion: Hormone replacement therapy after a diagnosis of breast cancer. Menopause 2:73-80, 1995.
48. Nilsson K, Heimer G: Low dose oestradiol in the treatment of urogenital oestrogen deficiency - a pharmacokinetic and pharmacodynamic study. Maturitas 13:121-127, 1992.
49. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density of postmenopausal women with breast cancer. N Engl J Med 313:852-857, 1992.
50. Stampfer M, Colditz G: Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidermologic evidence. Prev Med 20:47-63, 1991.
51. Grodstein F, Stampfer M, Manson J, et al Postmenopausal estrogen and progestin use and the risk of cardiovascular disease N Engl J Med 335:453-461, 1996.
52. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish Adjuvant Trial. Br Med J 303:435-437, 1991.
53. US Department of Health and Human Services: Physical activity and health: A report of the Surgeon General. Atlanta. Centers for Disease Control and Prevention, 1996.
54. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 132:612-628, 1990.
55. Stampfer MJ, Hennekens CH, Manson JE, et al. A prospective study of vitamin E consumption and risk of coronary disease in women. N Engl J Med 328:1444-1449, 1993.
56. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106, 1994.
57. US Department of Health and Human Services: The health benefits of smoking cessation. Washington. DC, DHSS publication no (CDC)90-8416, 1990.